iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
India’s top drugmakers, Sun Pharmaceutical Industries (NSE:SUN) and Lupin Ltd (NSE:LUPN), are moving closer to developing affordable anti-obesity drugs as the country faces a growing health crisis. According to Mint, both companies have received approval from the Drugs Controller General of India (DCGI) to advance their obesity drug programs, aiming to provide cost-effective alternatives to expensive global treatments.
Sun Pharma has been cleared to launch a large-scale Phase III clinical trial for its oral semaglutide tablets, a promising development given the high demand for easier-to-use, non-injectable options. Meanwhile, Lupin has secured approval for a bioequivalence study to prove that its generic obesity pill performs similarly to the original version. These steps could pave the way for wider patient access in a market where obesity treatment remains limited and costly.
Currently, breakthrough drugs like Novo Nordisk’s Wegovy (CSE:NOVOb) and Eli Lilly’s Mounjaro (NYSE:LLY) are available but are prohibitively priced and largely limited to injections, restricting accessibility for many Indian patients. With generics entering the pipeline, experts suggest that treatment costs could drop significantly, improving access to millions struggling with obesity. However, doctors caution that misuse of such medications could pose risks, stressing the importance of strict medical supervision and regulatory safeguards.
India is facing a mounting obesity epidemic. A Lancet study projects the country could have nearly 450 million overweight and obese adults by 2050, putting immense pressure on its healthcare system. The push by Sun Pharma and Lupin to create affordable anti-obesity solutions could mark a turning point in tackling this challenge, offering new hope for patients while reinforcing India’s position in the global pharmaceutical market.
